Analysis of combinations of antiviral drugs and design of effective multidrug therapies

Antiviral Therapy

Volumn 1, Issue 1, 1996, Pages 9-20

  Prichard, Mark N ^a   Shipman Jr , Charles ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

COMPARATIVE STUDY; COMPUTER SIMULATION; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; HUMAN; REVIEW; THEORETICAL MODEL; VIRUS INFECTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MODELS, THEORETICAL; VIRUS DISEASES; VIRUS REPLICATION;

EID: 0029677209     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Allen LB, Quenelle DC, Westbrook L, Taylor BA, Prichard MN, Brazier AD, Hollingshead MG & Shannon WB. In vitro and in vivo enhancement of ddI activity against rauscher murine leukemia virus by ribavirin. Antiviral Research 1995; 27:317-323.
2. Balzarini J, Karlsson A., Perez-Perez M-J, Camarasa M-J, Tarpley WG & De Clercq E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. Journal of Virology 1993; 67:5353-5359.
3. Bauer DJ. The antiviral and synergistic actions of isatin thiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice. British Journal of Experimental Pathology 1954; 28:105-114.
4. Belen'kii MS & Schinazi RF. Multiple drug effect analysis with confidence interval. Antiviral Research 1994; 25:1-11.
5. Berenbaum MC. The expected effect of a combination of agents; the general solution. Journal of Theoretical Biology 1985; 114:413-431.
6. Berenbaum MC. What is Synergy? Pharmacology Reviews 1989; 41:93-141.
7. Bilello JA, Bilello PA, Prichard MN, Robins T & Drusano GL. Reduction of the in vitro activity of Abbott (A)77003, an inhibitor of the human immunodeficiency virus protease, by α1-acid glycoprotein. Journal of Infectious Diseases 1994; 171:546-551.
8. Birch CJ, Tyssen DP, Tachedjian G, Doherty R, Hayes K, Mijch A & Lucas CR. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and sensitive herpes simplex virus infection. Journal of Infectious Diseases 1992; 166:108-112.
9. Biron KK. Ganciclovir-resistant human cytomegalovirus clinical isolates: resistance mechanisms and in vitro susceptibility to antiviral agents. Transplantation Proceedings 1991; 23:162-167.
10. Bliss CI. The toxicity of poisons applied jointly. Annals of Applied Biology 1939; 26:585-615.
11. Buckheit RW, Fliakas-Boltz V, Decker WD, Roberson JL, Pyle CA, White EL, Bowden BJ, McMahon JB, Boyd MR, Bader JP, Nickell DG, Barth H & Antonucci TK. Biological and biochemical anti-HIV-1 activity of the benzothiadiazine class of non-nucleoside reverse transcriptase inhibitors. Antiviral Research 1994; 25:43-56.
12. Buckheit RW, Fliakas-Boltz V, Decker WD, Roberson JL, Stup TL, Pyle CA, White EL, McMahon JB, Currens MJ, Boyd MR & Bader JP. Comparative anti-HIV evaluation of diverse HIV-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Research 1995; 26:117-132.
13. Buckheit RW, Hollingshead MG, Germany-Decker J, White EL, McMahon JB, Allen LB, Ross LJ, Decker WD, Westbrook L, Shannon WM, Weislow O, Bader JP & Boyd MR. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new non-nucleoside reverse transcriptase inhibitor. Antiviral Research 1993; 21:247-265.
14. Bunow B & Weinstein JN. COMBO: a new approach to the analysis of drug combinations in vitro. Annals of the New York Academy of Sciences 1990; 616:490-194.
15. Bush K. β-lactamase inhibitors from laboratory to clinic. Clinical Microbiology Reviews 1988; 1:109-123.
16. Butler KM, De Smet MD, Husson RN, Mueller B, Manjunath K, Montrella K, Lovato G, Jarosinski P, Nussenblatt RB & Pizzo PA. Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. Journal of Pediatrics 1992; 120:483-486.
17. Byrnes VW, Sardana VV, Schlief WA, Condra JH, Waterbury JA, Wolfgang JA, Long WJ, Schneider CL, Schlabach AJ, Wolanski BS, Graham DJ, Gotleib L, Rhodes A, Titus A, Roth E, Blahy OM, Quintero JC, Staszewski S & Emini EA. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase to nonnucleoside inhibitors. Antimicrobial Agents & Chemotherapy 1993; 37:1576-1579.
18. Carter WH, Jones DE & Carchman RA. Application of response surface methods for evaluating interactions of soman, atropine, and pralidioxime chloride, Fundamental and Applied Toxicology 1985; 5 (Suppl.):S232-241.
19. Chatis PA & Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrobial Agents & Chemotherapy 1992; 36:1589-1595.
20. Chong K-T, Pagano PJ & Hinshaw RP. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′ azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrobial Agents & Chemotherapy 1993; 38:288-293.
21. Chou J & Chou T-C. Dose effect analysis with macrocomputers. 1987. Amsterdam: Elsevier Science Publishers BV.
22. Chou T-C & Rideout DC. Synergism and antagonism in chemotherapy. 1991. New York: Academic Press.
23. Chou T-C & Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984; 22:27-55.
24. Chow Y-K, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC & D'Aquila RT. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature, London 1993; 361:650-654.
25. Coen DM. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Research 1991; 15:287-300.